Voroshil Gukasyan

Recent publications · Crossref

5 total works indexed

1. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

   · 2018 · cited 473x

2. Single-Dose Psilocybin Treatment for Major Depressive Disorder

   · 2023 · cited 466x

3. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

   · 2015 · cited 406x

4. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

   · 2022 · cited 354x

5. Genome-wide analysis identifies novel susceptibility loci for myocardial infarction

   · 2021 · cited 261x

via Crossref · CC0

Wikidata facts

Image

Voroshil Gukasyan.jpg